Skip to content

Evaluate non-invasive markers of liver fibrosis in the psoriasis population

Evaluate non-invasive markers of liver fibrosis in the psoriasis population 1

Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. People with psoriasis taking methotrexate may be at increased risk of developing liver fibrosis compared with the general population. To evaluate the diagnostic accuracy of noninvasive methods to detect fibrosis compared with liver biopsy (reference standard) in people with psoriasis taking methotrexate. People with psoriasis taking methotrexate may be at increased risk of developing liver fibrosis compared to the general population. Evaluate non-invasive markers of liver fibrosis in the psoriasis population. Namely transient elastography, standard liver function tests and P3NP. Evaluate the impact of psoriasis disease severity and comorbidities including metabolic syndrome on response to treatment in patients with psoriasis.

Evaluate non-invasive markers of liver fibrosis in the psoriasis population 2BACKGROUND People with psoriasis taking methotrexate may be at increased risk of developing liver fibrosis compared to the general population. Diagnostic accuracy of non-invasive markers of liver fibrosis in patients with psoriasis taking methotrexate: A systematic review and meta-analysis; Maybury C, Samarasekera E, Douiri A, Barker J, Smith C; British Journal of Dermatology (Mar 2014). OBJECTIVES To evaluate the diagnostic accuracy of non-invasive methods to detect fibrosis compared to liver biopsy (reference standard) in people with psoriasis taking methotrexate. 2. Evaluate non-invasive markers of liver fibrosis in the psoriasis population. Namely transient elastography, standard liver function tests and P3NP. 3. Evaluate the impact of psoriasis disease severity and comorbidities including metabolic syndrome on response to treatment in patients with psoriasis. Psoriasis is thought to be a T cell-driven disease, with the Th1 and Th17 cell populations playing a major role. Moreover, prevalence of advanced liver fibrosis was 8.1 in psoriatic patients compared with 3.6 in the control group ( p 0.05).

Objective To evaluate the use of transient elastography (TE) and FibroTest (FibroSURE in the United States), an indirect serum marker of fibrosis, in this population. Various noninvasive tests of hepatic fibrosis have been examined for monitoring patients with chronic hepatitis C virus (HCV) infection. These researchers developed a decision analytic model of non-invasive testing strategies in a hypothetical patient population with genotype 1 hepatitis C virus infection, with no contraindications to liver biopsy. Measurement of serum PON1 activity has been proposed as a potential test for the evaluation of liver function, however, it clinical acceptance is limited due to instability and toxicity of its substrate, paraoxon 71. It generates a score that is correlated with the degree of liver damage in people with a variety of liver diseases. For the diagnosis of significant liver fibrosis (F or 2) non invasive tests cannot yet replace liver biopsy.

Diagnostic Accuracy Of Non-invasive Markers Of Liver Fibrosis In Patients With Psoriasis Taking Methotrexate: A Systematic Review And Meta-analysis

Laser to Acitretin Therapy in the Management of Palmoplantar Psoriasis Resource links provided by NLM: 3Therefore, assessment of CPA may be the best means to increase the accuracy of noninvasive markers for clinical use (Fig. 5). Kock Y, Hammar H. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. Cirrhosis is a condition in which the liver does not function properly due to long-term damage. Typically, the disease comes on slowly over months or years. Liver size can be enlarged, normal, or shrunken in people with cirrhosis. Ascites, accumulation of fluid in the peritoneal cavity (space in the abdomen), gives rise to flank dullness (needs about 1500 ml to detect flank dullness). There is now a validated and patented combination of 6 of these markers as non-invasive biomarker of fibrosis (and so of cirrhosis): FibroTest. Ultrasound is routinely used in the evaluation of cirrhosis. Evaluation of liver fibrosis by transient elastography (Fibroscan) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Levels of the marker for liver fibrosis increased gradually, reaching a maximum of 8 mcg/L. Increasingly, clinicians who treat psoriasis in England have begun discussing noninvasive methods to evaluate patients for fatty liver disease, Debroy Kidambi said. Non-invasive markers used for staging liver fibrosis are now as accurate as liver biopsy for differentiating patients with mild fibrosis from those with significant fibrosis and some of these tests may be more accurate at detecting fibrosis than liver biopsy and this is limiting their validation 34. Whilst we still do not yet have a reliable enough non-invasive test of liver function to avoid the need for liver biopsy in all patients, further studies to evaluate the risk and validate these methods in our patients are still required. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the abse. The Fibroscan and the Fibrotest are two novel, non-invasive methods that might be able to assess MTX-induced hepatic fibrosis. Evaluating the accuracy and feasibility of the Fibroscan and Fibrotest to detect significant MTX-induced liver fibrosis in psoriasis patients. In this population, Fibrotest accurately predicted the presence of significant liver fibrosis while the Fibroscan accurately predicted the absence of significant liver fibrosis in MTX users.

Jama Network

Comparison of Liver Biopsy with Transient Elastography as a Non-invasive Method for Assessment of Liver Fibrosis. 8 Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourliere M, de LV: Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. M. Liver stiffness cut off values in HCV patients: validation and comparison in an independent population. Though liver biopsy remains the gold standard for assessing liver fibrosis, non invasive procedures are being developed for many years to overcome its complications (Bravo et al. Several quantitative elastography techniques (see Table 1) were proposed to assess liver stiffness as a marker of pathological state. This standardization favors the consistency of the results obtained whatever the operator, the studied population and the etiology of the patients. 2007Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease, Gut, 56 7Jul), 968 973.